{
  "id": 327808,
  "title": "Ractigen Therapeutics completes trial enrolment for ALS drug",
  "url": "https://urgent.news/2026/08/07/ractigen-therapeutics-completes-trial-enrolment-for-als-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T08:26:41.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/ractigen-therapeutics-completes-trial-enrolment-for-als-drug-158335.html"
  },
  "original_language": "en",
  "account": "NANTONG, China - Ractigen Therapeutics, a clinical-stage biotech firm focusing on RNA therapies, has announced the completion of patient enrollment and initial dosing in its Phase II ALS drug trial for RAG-17. This milestone follows the successful dosing of the first participant on January 13, 2026, and marks the end of patient enrollment across all five trial sites. RAG-17, an investigational siRNA therapy targeting SOD1 mutations in amyotrophic lateral sclerosis (ALS), is developed using Ractigen's SCAD™ platform. The Phase II trial, NCT06556394, aims to assess the drug's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in SOD1-mutation patients. With regulatory interactions and potential approval on the horizon, Ractigen remains focused on advancing RAG-17 through the accelerated development pathway designated by the FDA and selected for the CARE Program by the National Medical Products Administration.",
  "summary": "Ractigen Therapeutics completed patient enrolment and initial dosing across all cohort groups in its Phase II clinical trial evaluating RAG 17 for ALS treatment",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}